L&S Knock-Out QBY/ DE000LX2F6C9 /
5/21/2024 8:14:06 AM | Chg.-0.010 | Bid5/21/2024 | Ask5/21/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.470EUR | -2.08% | 0.470 Bid Size: 7,000 |
0.510 Ask Size: 7,000 |
Q.BEYOND AG NA O.N. | 0.3613 - | 12/31/2078 | Call |
GlobeNewswire
7:30 AM
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
2:25 AM
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
2:15 AM
West Coast Community Bancorp and 1st Capital Bancorp Announce Agreement to Merge
GlobeNewswire
5/20
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
GlobeNewswire
5/20
PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders
GlobeNewswire
5/20
INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 2024
GlobeNewswire
5/20
Zoom Video Communications Reports Financial Results for the First Quarter of Fiscal Year 2025
GlobeNewswire
5/20
Equinix (EQIX) Faces Class Action, Multiple Regulatory Investigations Related to Manipulated Account...
Newsfile Corp
5/20
KPMG Upgrades GenAI Audit Assistant, Unveiling New Capabilities To Empower Its 9,000+ Audit Partners...
GlobeNewswire
5/20
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 Intern...
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...